Using human ScFv to develop anti CD19 CAR cells to answer the previous problem of human anti mouse immune response, while using murine products has been addressed, [54] with a hope of using it for anti-tumor activity of CD19 CAR T cells, along with further clinical trials and in vivo studies. The gene discussed is CD19; the disease is neoplasm.